Triple-Negative Breast Cancer

When a breast cancer biopsy is analyzed, pathologists test for three molecular markers: the estrogen receptor (ER), the progesterone receptor (PR), and the HER2 protein. In triple-negative breast cancer, all three tests come back negative. This means the cancer cells are not being fueled by estrogen or progesterone signals, and they are not overproducing the HER2 growth protein.

This has important treatment implications. Therapies that block estrogen — like tamoxifen or aromatase inhibitors — and drugs that target HER2 — like trastuzumab — are not effective against TNBC. As a result, chemotherapy has historically been the main systemic treatment. However, the treatment landscape for triple-negative breast cancer has evolved significantly in recent years, with immunotherapy drugs and PARP inhibitors (for those with BRCA mutations) now approved for certain patients.

Triple-negative breast cancer tends to grow more quickly than hormone-receptor-positive types, and it is more common in younger women and in women of African American descent. While it can feel more unsettling to receive this diagnosis, it is important to know that TNBC often responds well to chemotherapy, and ongoing research continues to expand the treatment options available.

Triple-negative breast cancer represents about 10–15% of all breast cancers, and it has historically been harder to treat because it doesn't respond to some of the most commonly used targeted therapies. Understanding what triple-negative means helps explain why your oncologist may recommend a different treatment approach than someone with a hormone-receptor-positive tumor.

Research into TNBC has accelerated considerably, and several new therapies have been approved in recent years. Immunotherapy, antibody-drug conjugates, and PARP inhibitors are opening new treatment pathways. Staying connected with an oncologist who specializes in breast cancer ensures you have access to the most current options, including clinical trials.